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Topical phenylephrine, an agent used to facilitate naso-
tracheal intubation and prevent nasal mucosal bleeding, can
cause severe hypertension in some patients, secondary to its
stimulation of alpha-adrenergic receptors. Moreover, a high
incidence of pulmonary edema is found in patients whose
phenylephrine administration is followed by treatment with
beta-blocking agents. We report a case of acute pulmonary
edema in a pediatric patient who developed severe hyperten-
sion after the inadvertent administration of a large dose of
topical nasal phenylephrine, followed by beta-adrenergic
antagonists (esmolol).
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INTRODUCTION
Nasotracheal intubation is routinely performed
in maxillofacial surgery to optimize the surgical
field. Phenylephrine is applied to the nasal mu-
cosa before nasotracheal intubation because its
vasoconstrictive properties facilitate insertion of
the tube. Phenylephrine is predominately an
alpha-adrenergic agonist. Therefore, if significant
systemic absorption occurs following topical
administration, adverse cardiopulmonary conse-
quences, such as hypertensive crisis, reflex brad-
ycardia and ventricular arrhythmias, may occur.
Pulmonary edema is more likely to develop when
systemic absorption of topical phenylephrine is
followed by beta-adrenergic antagonists in an
attempt to control phenylephrine-induced hyper-
tension.
1-3
We report a case of acute pulmonary edema
following administration of a 1.5 ml dose of 0.5%
phenylephrine during the induction of general
anesthesia in a pediatric patient undergoing den-
tigerous cyst resection.
CASE REPORT
A 13-year-old boy was admitted for dentigerous
cyst resection. On admission, his physical exami-
nation appeared normal and there was no evi-
dence of pulmonary or cardiac disease. The
patient had no significant past medical or family
history. His weight and height were 76 kg and
1.65 meters, respectively.
No premedication was administered. Monitors
(ECG, blood pressure cuff and pulse oximetry)
were applied for general anesthesia. Preoperative
vital signs were as follows: heart rate 117 beats
min
-1, BP 136/73 mmHg and SpO2 98%. After the
administration of propofol (120 mg) and vecuroni-
um (9 mg), anesthesia was induced with additio-
nal sevoflurane (up to 4 vol%) by mask in a mix-
ture of oxygen and nitrous oxide (FiO2, 0.5). One
minute later, 0.5% phenylephrine was sprayed
into both nostrils, using a multiorificed cannula to
ensure uniform distribution on the nasal mucosa.
However, 1.5 ml of 0.5% phenylephrine was ad-
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ministered instead of the intended dose of 0.5 ml.
The patient was then given alfentanil (1 mg) and
atropine sulfate (0.5 mg) to blunt the hemodyna-
mic response to intubation. Two minutes after the
phenylephrine intranasal spray administration,
the patient's BP was 135/63 mmHg, and his heart
rate reduced to 48 beats min
-1.
Atropine sulfate (0.5 mg) was then administered
to control bradycardia. Two minutes later, BP rose
to 208/130 mmHg, and heart rate increased to 147
beats min
-1. A 5 mg dose of esmolol, a beta-ad-
renergic antagonist, was then given, followed by
an additional 5 mg dose. After three minutes, the
monitors displayed a reduced SpO2. With a FiO2
of 0.5, SpO2 was reduced to 88%.
An endotracheal tube was inserted immedi-
ately, and manual ventilation with 100% oxygen
was recommenced. At the time of nasotracheal
intubation, BP was 142/91 mmHg and heart rate
was 128 beats min
-1. Auscultation revealed crepi-
tations which were heard throughout the chest,
and a blood-stained frothy fluid was aspirated
from the trachea using a suction catheter via the
endotracheal tube. A working diagnosis of pulmo-
nary edema was entertained at that time, and
intratracheal suctioning was performed several
additional times. Turbutaline sulfate (0.5 mg) was
injected subcutaneously, and furosemide (10 mg)
was administered intravenously. Morphine (5 mg)
and midazolam (3 mg) were also administered
intravenously for sedation.
Five minutes after nasotracheal intubation, SpO2
increased to above 90%, and the intratracheal
secretions decreased. Fifteen minutes post intuba-
tion, SpO2 had increased to 100% with a FiO2 of
1.0, BP was 117/67 mmHg and heart rate was 134
beats min
-1. Following insertion of a Foley cathe-
ter, urine output was measured in the operating
room. 300 ml of a blood-stained, frothy fluid was
aspirated from the trachea, and urine output was
300 ml. The amount of intravenous normal saline
administered was 450 ml over 3.5 hours, preopera-
tively. Although oxygen saturation had returned
to the normal range at that point, surgery was
postponed pending a consultation with specialists.
The patient was transferred to the intensive care
unit (ICU).
In the ICU, chest radiography, taken immedi-
ately after transfer, showed a diffuse homogenous
alveolar infiltrate (Fig. 1). Ventilation was con-
trolled using a ventilator in the synchronized
intermittent mandatory ventilation (SIMV) mode,
with a positive end expiratory pressure (PEEP)
and FiO2 of 5 cm H2O and 0.5, respectively.
Midazolam was administered for sedation in the
ICU during ventilatory care. Six hours after being
transferred to the ICU, these radiographic abnor-
malities had almost completely resolved (Fig. 2).
Extubation was possible within thirty hours, and
no further problems were encountered.
Fig. 1. Chest radiograph taken immediately after transfer
to the intensive care unit. Diffuse bilateral pulmonary
infiltration is shown in both lung fields.
Fig. 2. Chest radiograph taken 6 hours after admission to
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DISCUSSION
Acute onset pulmonary edema in the absence of
airway obstruction is rarely encountered during
the induction of general anesthesia. We describe
a case of pulmonary edema in a pediatric patient
following severe hypertension with tachycardia.
We believe the most likely etiology to be an idio-
syncratic response to medications, specifically
topical phenylephrine followed by esmolol.
In otorhinolaryngology, the most commonly
used topical vasoconstrictors are oxymetazoline
(0.025-0.05%), cocaine (4-10%), and phenylephrine
(0.25-1%).
4 Phenylephrine is predominately an
alpha-adrenergic agonist and significant systemic
absorption can occur after topical administration.
The intraocular use of large doses of pheny-
lephrine has been reported to cause severe cardio-
vascular compromise and possibly pulmonary
edema.
5-7 Cardiopulmonary compromise may also
occur after topical phenylephrine administra-
tion.
1-3 Hypertension, secondary to alpha-adren-
ergic stimulation, is associated with increased
peripheral vascular resistance (increased after-
load) which can induce left ventricular failure.
The resulting elevation in capillary pressure may
trigger pulmonary edema.
Increased systemic vascular resistance increases
left ventricular ejection impedance and end-dias-
tolic volumes and pressures. In the face of in-
creased peripheral vascular resistance, cardiac
output may be further diminished, leading to car-
diac congestion and left heart failure. The ability
to increase heart rate and contractility are impor-
tant compensatory mechanisms to preserve car-
diac output under these circumstances. Although
the majority of healthy patients tolerate mild
degrees of myocardial depression without clinical
sequelae, impairment of the hemodynamic com-
pensatory mechanisms may result in pulmonary
edema. Beta-adrenergic antagonists can impair
these mechanisms.
8
An initial dose of up to 0.5 mg (25 g/kg) of μ
phenylephrine has been suggested in the New
York State Guidelines.
1 This assumes 100% ab-
sorption of the administered phenylephrine dose.
In our case, 1.5 ml of 0.5% phenylephrine, an
amount that exceeds the recommended dose, was
given inadvertently. Hypertension and tachy-
cardia then occurred. Tachycardia was observed
after atropine sulfate administration. Atropine
sulfate can potentiate hypertension by inhibiting
reflex bradycardia, leading to tachycardia.
9
The hemodynamic parameters of the patient
were BP of 208/130 mmHg and heart rate of 147
beats min
-1. In a severe hypertensive state, pul-
monary edema may occur more easily because
esmolol will decrease BP and heart rate. Cardio-
vascular collapse occurs more frequently in
patients who develop pulmonary edema and who
have received labetalol, rather than esmolol.
1 The
shorter duration of beta-blocking activity of
esmolol and the small dose administered in the
present case may have prevented pulmonary
edema from progressing to cardiovascular col-
lapse.
To prevent future occurrences of the type of
cardiopulmonary compromise witnessed in this
case, it is important to recognize the possibility of
abnormal absorption of topical alpha-agonists and
to anticipate hypertensive events. If the hyperten-
sion begins to spontaneously resolve, no further
medical therapy is warranted. However, if the
increased pressure is severe or proves persistent,
the administration of vasodilators and alpha-ad-
renergic antagonists are recommended.
10,11 These
agents are safer in this scenario than beta-ad-
renergic antagonists because they do not reduce
the ability of a stressed myocardium to increase
contractility and heart rate.
In conclusion, we describe a pediatric patient
who experienced pulmonary edema and severe
hypertension related to a systemic effect after the
topical application of a large dose of phenyle-
phrine and the subsequent administration of
esmolol. The minimal amount of phenylephrine
needed to achieve vasoconstriction should be
administered to prevent nasal mucosal bleeding
during nasotracheal intubation. Hemodynamic
parameters should then be closely monitored and
any necessary treatment should be given without
delay.
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